Mycobacterium tuberculosis

Principles and Practice of Clinical Bacteriology: Second Edition

Volumn , Issue , 2006, Pages 159-169

  Gillespie, Stephen H ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Directly observed therapy short course (DOTS) strategy; Extrapulmonary tuberculosis treatment; Lymph node tuberculosis and tuberculosis meningitis; Multiple drug resistant tuberculosis (MDRTB); Mycobacterium tuberculosis

Indexed keywords

EID: 84876874063     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470017968.ch10     Document Type: Chapter

References (98)

1. Adjers-Koskela, K. and Katila, M. L. (2003) Susceptibility testing with th anual mycobacteria growth indicator tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistan uberculosis. J Clin Microbiol 41, 1235-1239.
2. Advisory Committee on Dangerous Pathogens. (2001) The management, design and operation of microbiological containment laboratories.
3. Alland, D., Kalkut, G. E., Moss, A. R. et al. (1994) Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventiona pidemiologic methods. N Engl J Med 330, 1710-1716.
4. Anon. (2000) Diagnostic standards and classification of tuberculosis in adult and children. Am J Respir Crit Care Med 161, 1376-1395.
5. Association of State and Territorial Public Health Directors and Centers for Disease Control. (1995) Mycobacterium tuberculosis: assessing you aboratory.
6. Banner, A. S. (1979) Tuberculosis. Clincal aspects and diagnosis. Arch Intern Med 139, 1387-1390.
7. Beggs, C. B., Noakes, C. J., Sleigh, P. A. et al. (2003) The transmission o uberculosis in confined spaces: an analytical review of alternative epidemiologica odels. Int J Tuberc Lung Dis 7, 1015-1026.
8. Belanger, A. E., Besra, G. S., Ford, M. E. et al. (1996) The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cel all arabinan biosynthesis that is the target for the antimycobacterial dru thambutol. Proc Natl Acad Sci U S A 93, 11919-11924.
9. Bemer, P., Bodmer, T., Munzinger, J. et al. (2004) Multicenter evaluation o he MB/BACT system for susceptibility testing of Mycobacteriu uberculosis. J Clin Microbiol 42, 1030-1034.
10. Bhattacharya, M., Dietrich, S., Mosher, L. et al. (1998) Cross-contamination of specimens with Mycobacterium tuberculosis: clinical significance, causes, and prevention. Am J Clin Pathol 109, 324-330.
11. Bifani, P. J., Mathema, B., Kurepina, N. E. and Kreiswirth, B. N. (2002) Global dissemination of the Mycobacterium tuberculosis W-Beijing famil trains. Trends Microbiol 10, 45-52.
12. Billington, O. J., McHugh, T. D. and Gillespie, S. H. (1999) Physiological cos f rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 43, 1866-1869.
13. Blower, S. M., McLean, A. R., Porco, T. C. et al. (1995) The intrinsic transmissio ynamics of tuberculosis epidemics. Nat Med 1, 815-821.
14. Braden, C. R. (1995) Infectiousness of a university student with laryngeal an avitary tuberculosis. Clin Infect Dis 21, 565-570.
15. Breathnach, A. S., de Ruiter, A., Holdsworth, G. M. et al. (1998) An outbrea f multi-drug-resistant tuberculosis in a London teaching hospital. J Hosp Infect 39, 111-117.
16. Brewer, T. F. (2000) Preventing tuberculosis with bacillus Calmette-Gueri accine: a meta-analysis of the literature. Clin Infect Dis 31 (Suppl. 3), S64-S67.
17. Brosch, R., Gordon, S. V., Marmiesse, M. et al. (2002) A new evolutionar cenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci U S A 99, 3684-3689.
18. Brosch, R., Pym, A. S., Gordon, S. V. and Cole, S. T. (2001) The evolution o ycobacterial pathogenicity: clues from comparative genomics. Trends Microbiol 9, 452-458.
19. Cambau, E., Sougakoff, W., Besson, M. et al. (1994) Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones durin reatment with ofloxacin. J Infect Dis 170, 479-483.
20. Canetti, G. (1955) The Tubercle Bacillus in the Pulmonary Lesion of Man, Springer, New York, NY.
21. Canetti, G., Le Lirzin, M., Porven, G. et al. (1968) Some comparative aspect f rifampicin and isoniazid. Tubercle 49, 367-376.
22. Cole, S. T., Brosch, R., Parkhill, J. et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544.
23. Collins, C. H., Grange, J. M. and Yates, M. D. (1997) Tuberculosis Bacteriology: Organization and Practice, 2nd edn, Butterworh Heineman, London.
24. Conaty, S. J., Claxton, A. P., Enoch, D. et al. (2005) The clinical interpretatio f nucleic acid amplification tests for tuberculosis. Do rapid tests chang reatment decisions? J Infect 50, 187-192.
25. Cooksey, R. C., Morlock, G. P., McQueen, A. et al. (1996) Characterization o treptomycin resistance mechanisms among Mycobacterium tuberculosi solates from patients in New York City. Antimicrob Agents Chemother 40, 1186-1188.
26. Corbett, E. L., Watt, C. J., Walker, N. et al. (2003) The growing burden o uberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163, 1009-1021.
27. Crofton, J. and Mitchison, D. A. (1948) Streptomycin resistance in pulmonar uberculosis. Br Med J 2, 1009-1015.
28. Cruickshank, D. B. (1952) Bacteriology, In Modern Practice in Tuberculosis. (ed. T. H. Sellors and J. L. Livingstone) p. 53 Butterworth; London.
29. Dauendorffer, J. N., Guillemin, I., Aubry, A. et al. (2003) Identification o ycobacterial species by PCR sequencing of quinolone resistance-determinin egions of DNA gyrase genes. J Clin Microbiol 41, 1311-1315.
30. David, H. L. (1970) Probability distribution of drug-resistant mutants i nselected populations of Mycobacterium tuberculosis. Appl Microbiol 20, 810-814.
31. Davies, A. P., Newport, L. E., Billington, O. J. and Gillespie, S. H. (1999) Length of time to laboratory diagnosis of Mycobacterium tuberculosis infection: comparison of in-house methods with reference laboratory results. J Infect 39, 205-208.
32. de C. Ramos M., Soini, H., Roscanni, G. C. et al. (1999) Extensive crosscontaminatio f specimens with Mycobacterium tuberculosis in eference laboratory. J Clin Microbiol 37, 916-919.
33. Dickinson, J. M., Mitchison, D. A., Lee, S. K. et al. (1977) Serum rifampici oncentration related to dose size and to the incidence of the 'flu' syndrome during intermittent rifampicin administration. J Antimicrob Chemother 3, 445-452.
34. Dormandy, T. (1999) The White Death: A History of Tuberculosis, The Hambeldon Press, London.
35. Drake, J. W. (1999) The distribution of rates of spontaneous mutation ove iruses, prokaryotes, and eukaryotes. Ann N Y Acad Sci 870, 100-107.
36. Drobniewski, F. A., Caws, M., Gibson, A. and Young, D. (2003) Modern laborator iagnosis of tuberculosis. Lancet Infect Dis 3, 141-147.
37. Dubos, R. and Dubos, J. (1952) The White Plague: Tuberculosis, Man and Society, Rutgers University Press, Piscataway, NJ.
38. Dye, C. (2000) Tuberculosis, 2000-2010: control, but not elimination. Int J Tuberc Lung Dis 4, S146-S152.
39. Elliott, A. M., Berning, S. E., Iseman, M. D. and Peloquin, C. A. (1995) Failure of drug penetration and acquisition of drug resistance in chroni uberculous empyema. Tuber Lung Dis 76, 463-467.
40. Fox, W. and Mitchison, D. A. (1975) Short-course chemotherapy for pulmonar uberculosis. Am Rev Respir Dis 111, 325-353.
41. Fox, W., Ellard, G. A. and Mitchison, D. A. (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosi nits, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3, S231-S279.
42. Furesz, S. and Timball, M. T. (1963) The antibacterial activity of rifamycins. Chemotherapia 7, 200.
43. Gillespie, S. H. (2002) Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 46, 267-274.
44. Glynn, J. R. (1998) Resurgence of tuberculosis and the impact of HIV Infection. Br Med Bull 54, 579-593.
45. Hobby, G. L., Holman, A. P., Iseman, M. D. and Jones, J. M. (1973) Enumeratio f tubercle bacilli in sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother 4, 94-104.
46. Hoge, C. W., Fisher, L., Donnell, H. D. Jr. et al. (1994) Risk factors fo ransmission of Mycobacterium tuberculosis in a primary school outbreak: lack of racial difference in susceptibility to infection. Am J Epidemiol 139, 520-530.
47. Holmberg, S. D. (1990) The rise of tuberculosis in America before 1820. Am Rev Respir Dis 142, 1228-1232.
48. Honore, N. and Cole, S. T. (1994) Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 38, 238-242.
49. Honore, N., Perrani, E., Telenti, A. et al. (1993) A simple and rapid techniqu or the detection of rifampin resistance in Mycobacterium Leprae. Int J Lepr Other Mycobact Dis 61, 600-604.
50. Indrigo, J., Hunter, R. L. Jr and Actor, J. K. (2003) Cord factor trehalose, 6,6′-dimycolate (TDM) mediates trafficking events during mycobacteria nfection of murine macrophages. Microbiology 149, 2049-2059.
51. Iseman, M. D. and Madsen, L. A. (1991) Chronic tuberculous empyema wit ronchopleural fistula resulting in treatment failure and progressive dru esistance. Chest 100, 124-127.
52. Kaplan, G., Post, F. A., Moreira, A. L. et al. (2003) Mycobacterium tuberculosi rowth at the cavity surface: a microenvironment with failed immunity. Infection Immunity 71, 7099-7108.
53. Kato-Maeda, M., Rhee, J. T., Gingeras, T. R. et al. (2001) Comparing genome ithin the species Mycobacterium tuberculosis. Genome Res 11, 547-554.
54. Kaufmann, S. H. E. (2001) How can immunology contribute to the control o uberculosis. Nat Immunol 1, 20-30.
55. Kennedy, N., Fox, R., Uiso, L. et al. (1993) Safety profile of ciprofloxaci uring long-term therapy for pulmonary tuberculosis. J Antimicrob Chemother 32, 897-902.
56. Kim, B. J., Lee, S. H., Lyu, M. A. et al. (1999) Identification of mycobacteria pecies by comparative sequence analysis of the RNA polymerase gene (rpoB). J Clin Microbiol 37, 1714-1720.
57. Kuemmerer, J. M. and Comstock, G. W. (1967) Sociologic concomitants o uberculin sensitivity. Am Rev Respir Dis 96, 885-892.
58. Lebrun, L., Gonullu, N., Boutros, N. et al. (2003) Use of INNO-LIPA assa or rapid identification of mycobacteria. Diagn Microbiol Infect Dis 46, 151-153.
59. Lehman, J. (1946) Para-aminosalacylic acid in the treatment of tuberculosis. Lancet i, p. 15.
60. Lipsitch, M. and Levin, B. R. (1998) Population dynamics of tuberculosi reatment: mathematical models of the roles of non-compliance and bacteria eterogeneity in the evolution of drug resistance. Int J Tuberc Lung Dis 2, 187-199.
61. Lurie, M. B. (1931) The correlation between the histological changes and fat f living tubercle bacilli in the organs of tuberculous rabbits. J Exp Med 55, 31-56.
62. Lurie, M. B. (1964) Resistance to tuberculosis: experimental studies in nativa and acquired defence mechanisms.
63. Maguire, H., Dale, J. W., McHugh, T. D. et al. (2002) Molecular epidemiolog f tuberculosis in London, 1995-7 showing low rate of active transmission. Thorax 57, 617-622.
64. Mehta, J. B., Dutt, A., Harvill, L. and Mathews, K. M. (1991) Epidemiology o xtrapulmonary tuberculosis. A comparative analysis with pre-AIDS era. Chest 99, 1134-1138.
65. Middlebrook, G. and Cohn, M. L. (1953) Some observations on the pathogenicit f isoniazid resistant tubercle bacilli. Science 118, 297-299.
66. Middlebrook, G. and Dressler, S. H. (1954) Clinical evaluation of isoniazid. Am Rev Tuberc. 70, 1102-1103.
67. Moss, A. R., Alland, D., Telzak, E. et al. (1997) A city-wide outbreak of ultiple-drug-resistant strain of Mycobacterium tuberculosis in New York. Int J Tuberc Lung Dis 1, 115-121.
68. Rad, M. E., Bifani, P., Martin, C. et al. (2003) Mutations in putative mutato enes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg Infect Dis 9, 838-845.
69. Ramaswamy, S. and Musser, J. M. (1998) Molecular genetic basis of antimicrobia gent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 79, 3-29.
70. Rieder, H. L. (1999) Epidemiologic Basis of Tuberculosis Control. International Union Against Tuberculosis and Lung Diseases, Paris.
71. Riley, R. L., Mills, C. C., O'grady, F. et al. (1962) Infectiousness of ai rom a tuberculosis ward. Ultraviolet irradiation of infected air: comparative infectiousness of different patients. Am Rev Respir Dis 85, 511-525.
72. Ruddy, M., McHugh, T. D., Dale, J. W. et al. (2002) Estimation of the rat f unrecognized cross-contamination with Mycobacterium tuberculosi n London microbiology laboratories. J Clin Microbiol 40, 4100-4104.
73. Russell, D. G. (2001) Mycobacterium tuberculosis: here today, and her omorrow. Nat Rev Mol Cell Biol 2, 569-577.
74. Salo, W. L., Aufderheide, A. C., Buikstra, J. and Holcomb, T. A. (1994) Identification of Mycobacterium tuberculosis DNA in a pre-Columbian Peruvian mummy. Proc Natl Acad Sci USA 91, 2091-2094.
75. Scarparo, C., Piccoli, P., Rigon, A. et al. (2001) Direct identification of mycobacteri rom MB/BacT alert 3D bottles: comparative evaluation of tw ommercial probe assays. J Clin Microbiol 39, 3222-3227.
76. Scarparo, C., Piccoli, P., Rigon, A. et al. (2002) Evaluation of the BACTEC MGIT, 960 in comparison with BACTEC 460 TB for detection an ecovery of mycobacteria from clinical specimens. Diagn Microbiol Infect Dis 44, 157-161.
77. Schatz, A. and Waksman, S. A. (1944) Effect of streptomycin and other antibioti ubstances upon Mycobacterium tuberculosis and related organisms. Proc Soc Exp Biol Med 57, 244-248.
78. Scorpio, A. and Zhang, Y. (1996) Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous dru yrazinamide in tubercle bacillus. Nat Med 2, 662-667.
79. Shimao, T. (1987) Drug resistance in tuberculosis control. Tubercle 68, 5-18.
80. Sreevatsan, S., Pan, X., Stockbauer, K. E. et al. (1997b) Restricted structura ene polymorphism in the Mycobacterium tuberculosis complex indicate volutionarily recent globaládissemination. Proc Natl Sci USA 94, 9869-9874.
81. Sreevatsan, S., Pan, X., Zhang, Y. et al. (1997a) Analysis of the oxyR-ahpC region in isoniazid-resistant and-susceptible Mycobacterium tuberculosi omplex organisms recovered from diseased humans and animals i iverse localities. Antimicrob Agents Chemother 41, 600-606.
82. Sultan, L., Nyka, W., Mills, C. et al. (1960) Tuberculosis disseminators. A study of the variability of aerial infectivity of tuberculous patients. Am Rev Respir Dis 82, 358-369.
83. Supply, P., Mazars, E., Lesjean, S. et al. (2000) Variable human minisatellitelik egions in the Mycobacterium tuberculosis genome. Mol Microbiol 36, 762-771.
84. Supply, P., Warren, R. M., Banuls, A. L. et al. (2003) Linkage disequilibriu etween minisatellite loci supports clonal evolution of Mycobacterium tuberculosis in a high tuberculosis incidence area. Mol Microbiol 47, 529-538.
85. Telenti, A., Imboden, P., Marchesi, F. et al. (1993) Detection o ifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341, 647-650.
86. Tocque, K., Doherty, M. J., Bellis, M. A. et al. (1998) Tuberculosis notification in England: the relative effects of deprivation and immigration. Int J Tuberc Lung Dis 2, 213-218.
87. Tortoli, E. (2003) Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 16, 319-354.
88. van Creval, R., Karyadi, E., Preyers, F. et al. (2001) Increased productio f interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosi s related to the presence of pulmonary cavities. J Infect Dis 181, 1194-1197.
89. van Crevel, R., Ottenhoff, T. H. and van der Meer, J. W. (2002) Innate immunit o Mycobacterium tuberculosis. Clin Microbiol Rev 15, 294-309.
90. van Embden, J. D., Cave, M. D., Crawford, J. T. et al. (1993) Strain identificatio f Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 31, 406-409.
91. Vetter, E., Torgerson, C., Feuker, A. et al. (2001) Comparison of the BACTEC MYCO/F Lytic bottle to the isolator tube, BACTEC Plus Aerobic F/bottle, and BACTEC Anaerobic Lytic/10 bottle and comparison of the BACTEC Plus Aerobic F/bottle to the Isolator tube for recovery of bacteria, mycobacteria, and fungi from blood. J Clin Microbiol 39, 4380-4386.
92. von Gottberg, A., Sacks, L., Machala, S. and Blumberg, L. (2001) Utility o lood cultures and incidence of mycobacteremia in patients with suspecte uberculosis in a South African infectious disease referral hospital. Int J Tuberc Lung Dis 5, 80-86.
93. Walley, J. D., Khan, M. A., Newell, J. N. and Khan, M. H. (2001) Effectivenes f the direct observation component of DOTS for tuberculosis: andomised controlled trial in Pakistan. Lancet 357, 664-669.
94. Wang, S. X., Sng, L. H. and Tay, L. (2004) Preliminary study on rapi dentification of Mycobacterium tuberculosis complex isolates by the BD ProbeTec ET System. J Med Microbiol 53, 57-59.
95. Wilson, T. M., De Lisle, G. W. and Collins, D. M. (1995) Effect of inhA an atG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol 15, 1009-1015.
96. Yeager, H. Jr, Lacy, J., Smith, L. R. and LeMaistre, C. A. (1967) Quantitativ tudies of mycobacterial populations in sputum and saliva. Am Rev Respir Dis 95, 998-1004.
97. Yew, W. W., Lee, J., Wong, P. C. and Kwan, S. Y. (1992) Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepati ysfunction. Int J Clin Pharmacol Res 12, 173-178.
98. Zhang, Y., Heym, B., Allen, B. et al. (1992) The catalase-peroxidase gen nd isoniazid resistance of Mycobacterium tuberculosis. Nature 358, 591-593.